Second Primary Cancer Risks After Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers
Isaac Allen(Dana-Farber Cancer Institute), Antonis C. Antoniou(Weatherford College), Sally Vernon(Public Health England), Sophie Allen(Institute of Cancer Research), Clare Turnbull(Institute of Cancer Research), Joanna Pethick(NHS England), Andrew Bacon(National Health Service), Eva Morris(Open Data Institute), Alice Garrett(Institute of Cancer Research), Craig Knott(Insight Healthcare), Shilpi Goel(National Health Service), Fiona E. McRonald(NHS England), Bethany Torr(Royal Marsden NHS Foundation Trust), Marc Tischkowitz(University of Cambridge), Ying-Wen Wang(Kaohsiung Chang Gung Memorial Hospital), Sophie José(NHS England), Francesco Santaniello(Azienda Usl Toscana Centro), Lucy Loong(Institute of Cancer Research), Margreet Lüchtenborg(London Cancer), Yvonne Walburga Joko-Fru(National Health Service), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Catherine Huntley(National Health Service), Hend Hassan(University of Cambridge), Tameera Rahman(National Health Service), Katrina Lavelle(National Health Service), Diana Eccles(Princess Anne Hospital), Steven Hardy(University of Newcastle Australia)
Cited by 25
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k